Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
Phase 2
Completed
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2020-01-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 46
- Registration Number
- NCT02217566
Pharmacokinetic Study of JNJ-42756493 in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2015-01-08
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 8
- Registration Number
- NCT02218073
A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-08-07
- Last Posted Date
- 2015-11-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT02211079
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
Phase 3
Completed
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 992
- Registration Number
- NCT02207244
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
Phase 3
Completed
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 837
- Registration Number
- NCT02207231
A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
Phase 3
Completed
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 872
- Registration Number
- NCT02203032
A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy
- First Posted Date
- 2014-07-28
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 63
- Registration Number
- NCT02201251
A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-23
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 13
- Registration Number
- NCT02197884
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
Phase 3
Completed
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2014-07-21
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 706
- Registration Number
- NCT02195479
A Study of Golimumab in Participants With Active Ankylosing Spondylitis
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 208
- Registration Number
- NCT02186873
© Copyright 2025. All Rights Reserved by MedPath